Please login to the form below

Not currently logged in
Email:
Password:

Element of Pfizer's Viagra patent rejected

The US Patent and Trademark Office has partially rejected Pfizer's patent claim on Viagra due to similarities to a Chinese herb

An appeals board within the US Patent and Trademark Office has partially rejected Pfizer's patent claim on its erectile dysfunction drug, Viagra (sildenafil), ruling that an element of the drug was not significantly different to the Chinese medicine, Yin Yang Huo (Horny Goat Weed), and did not represent a new invention.

In coming to its conclusion on the ruling, the appeals board stated that the patent claim was the next logical step up from using Yin Yang Huo in the treatment of erectile dysfunction. A chemical ingredient of the herb was found to be similar to an enzyme inhibitor found in Viagra.

The claim formed part of a 2002 lawsuit filed by Pfizer against Eli Lilly over its rival drug, Cialis. Pfizer has until April 12, to seek a rehearing or appeal against the decision.

The patent in question is due to expire in 2019. This ruling only concerns one element of Viagra, and Pfizer could therefore still use the patent to block generic competition from the duplication of the drug's active ingredient (sildenafil citrate).

Pfizer's revenue for 2009 included $1.89bn from the sale of Viagra.

17th February 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...

Infographics